NVS:NYSENovartis AG Analysis

Novartis trades around $148, well above the DCF‑derived fair value of roughly $81, indicating the stock is currently overvalued despite a forward P/E of 15 that suggests earnings growth potential. The company delivers robust profitability with a 25.7% net margin, 75.9% gross margin, and a 30.8% operating margin, while generating $19.1 B of operating cash flow and a free cash flow yield that comfortably supports its 3.14% dividend yield. Dividend sustainability appears strong as the payout ratio sits near 56% and cash balances exceed $11 B, providing a cushion for continued payouts. Recent Phase III results for Fabhalta in IgA nephropathy add a promising pipeline catalyst, reinforcing the long‑term growth narrative. Technical indicators are mixed: the 20‑day SMA (≈151.9) sits above the current price, the RSI is at 40 (neither overbought nor oversold), and MACD shows a bearish divergence, while volume is trending down and the market direction is neutral. The stock faces typical pharma regulatory risk, but the recent positive trial data may mitigate short‑term concerns. Overall, the defensive health‑care sector, low beta (~0.39), and solid balance sheet suggest a stable risk profile, though the price premium limits upside in the near term.